Article ID Journal Published Year Pages File Type
10911340 Lung Cancer 2012 18 Pages PDF
Abstract
► The diagnosis of lung cancer involves the identification and complete classification of malignancy. ► New therapeutic options require specific subtyping of NSCLCs and, increasingly, the identification of therapeutically predictive molecular markers, to determine the safest and most effective choice of drugs. ► Small diagnostic sample size and tumour complexity often prevent specific subtyping on morphological grounds alone (NSCLC-NOS). ► Immunohistochemistry can predict the likely NSCLC subtype (squamous cell vs. adenocarcinoma) in most NSCLC-NOS cases. ► Tissue sampling should be maximized whenever feasible and deemed clinically safe, reducing the need for re-biopsy for additional studies. ► Tissue handling, processing and sectioning should minimize wastage and optimize use of tissue for diagnosis.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , , , , , , , , , ,